PMID- 31123922
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1534-6307 (Electronic)
IS  - 1523-3774 (Linking)
VI  - 21
IP  - 7
DP  - 2019 May 23
TI  - Treatment Strategies in ANCA-Associated Vasculitis.
PG  - 33
LID - 10.1007/s11926-019-0835-8 [doi]
AB  - PURPOSE OF REVIEW: The long-term survival of patients with antineutrophil 
      cytoplasmic antibody-associated vasculitis (AAV) has improved dramatically as a 
      direct result of evolving therapy. This review summarizes evidence-based 
      treatment strategies with currently approved immunosuppressive medications to 
      serve as a guide for practitioners in the management of patients with AAV. RECENT 
      FINDINGS: Targeted therapy aimed at minimizing treatment-related adverse effects 
      while optimizing effectiveness is a propagated approach. Such tailored therapy 
      considers disease severity and is especially warranted in those at high risk for 
      relapsing vasculitis. As treatment options for AAV become available, the need to 
      tailor therapy has become increasingly relevant to optimize patient outcomes.
FAU - Emejuaiwe, Nkechinyere
AU  - Emejuaiwe N
AD  - Rheumatology Section, Southeast Louisiana Veterans Health Care System, 2400 Canal 
      Street, New Orleans, LA, 70119, USA. nkechinyere.emejuaiwe@va.gov.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190523
PL  - United States
TA  - Curr Rheumatol Rep
JT  - Current rheumatology reports
JID - 100888970
RN  - 0 (Immunosuppressive Agents)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy/*therapy
MH  - Cyclophosphamide/*therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Mycophenolic Acid/*therapeutic use
MH  - *Plasma Exchange
MH  - Remission Induction
MH  - Rituximab/*therapeutic use
OTO - NOTNLM
OT  - Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
OT  - Cyclophosphamide
OT  - Mycophenolate mofetil
OT  - Plasma exchange
OT  - Remission induction, remission maintenance
OT  - Rituximab
EDAT- 2019/05/28 06:00
MHDA- 2020/10/02 06:00
CRDT- 2019/05/25 06:00
PHST- 2019/05/25 06:00 [entrez]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1007/s11926-019-0835-8 [pii]
AID - 10.1007/s11926-019-0835-8 [doi]
PST - epublish
SO  - Curr Rheumatol Rep. 2019 May 23;21(7):33. doi: 10.1007/s11926-019-0835-8.